A 56-year-old woman with adenocarcinoma of the right lung developed grade 2 hypo-thyroidism after four cycles of pembrolizumab plus chemotherapy, which was considered to be caused by pembrolizumab. After full clinical evaluation, the immune checkpoint inhibitors was not discontin-ued, and thyroid hormone was supplemented, patients were educated on medication, the drug dose was adjusted according to the thyroid function, and the thyroid function of the patient returned to normal after three months. In order to improve the safety of the clinical application of pembrolizumab, the mechanism, clinical characteristics, risk factors and prognosis of hypothyroidism induced by pembroli-zumab were further analyzed by reviewing the literature of the adverse reactions related to it.

1. 王英南, 张风宾, 张韶辰, 等. 帕博利珠单抗致食管癌患者甲状腺功能减退合并心肌损害一例报告[J]. 中国肿瘤生物治疗杂志, 2020, 27(9): 1068-1069. [Wang YN, Zhang FB, Zhang SC, et al. One case of hypothyroidism with myocardial damage caused by pembrolizumab in the treatment for esophageal cancer[J]. Chi-nese Journal of Cancer Biotherapy, 2020, 27(9):1068-1069.] DOI: 10.3872/j.issn.1007-385x.2020.09.017.

2. Fujimoto D, Miura S, Yoshimura K, et al. A real-world study on the effectiveness and safety of pem-brolizumab plus chemotherapy for nonsquamous NSCLC[J]. JTO Clin Res Rep, 2021, 3(2): 100265. DOI: 10.1016/j.jtocrr.2021. 100265.

3. 姜彩虹, 王利. 纳武利尤单抗致甲状腺功能减退1例[J]. 药物流行病学杂志, 2019, 28(9): 624-625. [Jiang CH, Wang L. One case of hypothyroidism induced by nivolumab[J]. Chinese Journal of Pharmacoepidemi-ology, 2019, 28(9): 624-625.] DOI: 10.19960/j.cnki.issn1005-0698.2019. 09.016.

4. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis[J]. JA-MA Oncol, 2018, 4(2): 173-182. DOI: 10.1001/jamaoncol.2017.3064.

5. 李长龙, 舒家华, 李国兴, 等. 4个进口PD-1/PD-L1抑制剂不良反应信号的挖掘与评价[J]. 中国药房, 2022, 33(7): 873-878. [Li CL, Shu JH, Li GX, et al. Excavation and evaluation of adverse reaction signals of 4 kinds of imported PD-1/PD-L1 inhibitors[J]. China Pharmacy, 2022, 33(7):873-878.] DOI: 10.6039/j.issn. 1001-0408.2022.07.18.

6. 国家药品不良反应监测中心. 药品不良反应术语使用指南[S]. 2016.

7. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity manage-ment working group[J]. J Immunother Cancer, 2017, 5(1): 95. DOI: 10.1186/s40425-017-0300-z.

8. 王守正,李峻岭. 免疫检查点抑制剂所致免疫相关不良反应预测指标的研究进展[J]. 癌症进展, 2019, 17(19): 2242-2245, 2254. [Wang SZ, Li JL. Research progress of predictors of immune-related adverse reac-tions induced by immune checkpoint inhibitor[J]. Oncology Progress, 2019, 17(19): 2242-2245, 2254.] DOI: 10.11877/j.issn.1672-1535.2019.17.19.04.

9. Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors[J]. Nat Rev Endocrinol, 2021, 17(7): 389-399. DOI: 10.1038/s41574-021-00484-3.

10.de Moel EC, Rozeman EA, Kapiteijn EH, et al. Autoantibody development under treatment with im-mune-checkpoint inhibitors[J]. Cancer Immunol Res, 2019, 7(1): 6-11. DOI: 10.1158/2326-6066.

11.Okada N, Iwama S, Okuji T, et al. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study[J]. Br J Cancer, 2020, 122(6): 771-777. DOI: 10.1038/s41416-020-0736-7.

12.Chang LS, Barroso-Sousa R, Tolaney SM. Endocrine toxicity of cancer immunotherapy targeting im-mune checkpoints[J]. Endocr Rev, 2019, 40(1): 17-65. DOI: 10.1210/er.2018-00006.

13.Chalan P, Di Dalmazi G, Pani F, et al. Thyroid dysfunctions secondary to cancer immunotherapy[J]. J Endocrinol Invest, 2018, 41(6): 625-638. DOI: 10.1016/j.bulcan.2019.10.005.

14.Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in pa-tients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. DOI: 10.1200/JCO.2017.77.6385.

15.万宝玉, 邓鹏裔, 王朋, 等. 抗PD-1/PD-L1单抗药物致甲状腺不良反应的研究进展[J]. 华中科技大学学报(医学版), 2021, 50(2): 256-260. [Wan BY, Deng PY, Wang P, et al. A review of thyroid adverse events produced by PD-1/PD-L1 inhibitors[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2021, 50(2): 256-260.] DOI: 10.3870/j.issn.1672-0741.2021.02.022.

16.Kassi E, Angelousi A, Asonitis N, et al. Endocrine-related adverse events associated with im-mune-checkpoint inhibitors in patients with melanoma[J]. Cancer Med, 2019, 8(15): 6585-6594. DOI: 10.1002/cam4.2533.

17.顾卫琼.免疫检查点抑制剂致甲状腺损伤的诊治进展[J].诊断学理论与实践, 2021, 20(4): 338-342.[Gu WQ. Pro-gress in diagnosis and treatment of thyroid injury caused by immune checkpoint inhibitor[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(4): 338-342.] DOI: 10.16150/j.1671-2870.2021.04.002.

18.Muir CA, Clifton-Bligh RJ, Long GV, et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment[J]. J Clin Endocrinol Metab, 2021, 106(9): e3704-e3713. DOI: 10.1210/clinem/dgab263.

19.Cortellini A, Bersanelli M, Santini D, et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of im-mune-related adverse events[J]. Eur J Cancer, 2020, 128: 17-26. DOI: 10.1016/j.ejca.2019.12.031.

20.Imblum BA, Baloch ZW, Fraker D,et al. Pembrolizumab-induced thyroiditis[J]. Endocr Pathol, 2019, 30(2): 163-167. DOI: 10.1097/MJT.0000000000001367.

21.罗景梅,杨中策,潘俐,等. 免疫检查点抑制剂所致内分泌不良反应处理流程研究进展[J]. 解放军医学杂志, 2021, 46(2): 200-206. [Luo JM, Yang ZC, Pan L, et al. Research progress of treatment process on endocrine adverse reactions caused by immune checkpoint inhibitors[J]. Medical Journal of Chinese People's Liberation Army, 2021, 46(2): 200-206.] DOI: 10.11855/j.issn.0577-7402.2021.02.15.

22.中国临床肿瘤学会. 免疫检查点抑制剂相关的毒性管理指南[S]. 2019: 30-32.

23.樊鹏宇. 免疫检查点抑制剂相关内分泌副反应的研究进展[J]. 同济大学学报（医学版）, 2020, 41(5): 654-661. [Fan PY. Endocrine side-effects associated with immune checkpoint inhibitors[J]. Journal of Tongji University (Medical Science), 2020, 41(5): 654-661.] DOI: 10.16118/j.1008-0392.2020.05.019.

24.Zhai Y, Ye X, Hu F, et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study lever-aging US Food and Drug Administration adverse events reporting system[J]. J Immunother Cancer, 2019, 7(1): 286. DOI: 10.1186/s40425-019-0754-2.

25.谢婷婷, 王伟兰. 纳武利尤单抗注射液致甲状腺功能减退1例[J]. 中国药物应用与监测, 2021, 18(4): 274-276. [Xie TT, Wang WL. One case of hypothyroidism induced by nivolumab injection[J]. Chinese Journal of Drug Application and Monitoring, 2021, 18(4): 274-276.]DOI: 10.3969/j.issn.1672-8157.2021.04.019.

26.Khan U, Rizvi H, Sano D, et al. Nivolumab induced myxedema crisis[J]. J Immunother Cancer, 2017, 9(21): 13. DOI: 10.1186/s40425-017-0213-x.

27.Gummalla S, Manjunath M, Phillips B. Myxedema Coma: a life-threatening condition in patients using pembrolizumab[J]. Case Rep Endocrinol, 2020, 2020: 8855943. DOI: 10.1155/2020/8855943.

28.段炼, 王林杰, 斯晓燕, 等. 免疫检查点抑制剂相关内分泌不良反应的临床诊治建议[J]. 中国肺癌杂志, 2019, 22(10): 649-652. [Duan L, Wang LJ, Si XY, et al. Clinical diagnosis and treatment of immune-related adverse events of edocrine system related to immune checkpoint inhibitors[J]. Chinese Journal of Lung Cancer, 2019, 22(10): 649-652.] DOI: 10.3779/j.issn.1009-3419. 2019.10.08.

29.彭智, 袁家佳, 王正航, 等. ASCO/NCCN免疫治疗毒性管理指南解读[J]. 肿瘤综合治疗电子杂志, 2018, 4(2): 38-47. [Peng Z, Yuan JJ, Wang ZH, et al. Comments on ASCO/NCCN management guidelines of toxicities from immunotherapy[J]. Journal of Multidisciplinary Cancer Management (Electronic Version), 2018, 4(2): 38-47.]

30.曾洁, 罗骞, 朱莉娜, 等. 免疫检查点抑制剂对癌症患者甲状腺功能的影响[J]. 肿瘤药学, 2022, 12(2): 204-207. [Zeng J, Luo Q, Zhu LN, et al. The impact of immune checkpoint inhibitors on thyroid function of can-cer patients[J]. Anti-Tumor Pharmacy, 2022, 12(2): 204-207.] DOI: 10.3969/j.issn.2095-1264.2022.02.10.